Medherant's TEPI Patch® technology provides an excellent platform for the development of a wide range of transdermal products, including drugs where patch delivery was previously not viable and patches for sustained delivery of drugs over a prolonged period.
TEPI patch ibuprofen

The TEPI Patch technology utilises a pressure-sensitive adhesive developed by Bostik. The superior adhesion of TEPI Patches means that it remains in contact with the skin throughout the dosing period so the full dose is delivered. A range of TEPI Patch products have been shown in a standard lab test to have better adhesion than commercial products tested (see figure below).

The rate of drug release from the TEPI Patch can be tailored to meet the desired pharmacokinetic profile for the patients being treated by adjusting the excipients included in the formulation (see figure below). Due to the higher loading capacity of the adhesive, a wider range of excipients can be included. The high drug loading also means that less adhesive is needed to formulate the therapeutic dose so patches can be thinner and smaller.

Unlike other patch adhesives, no organic solvents are used in the manufacture of the TEPI Patch, so there is no need for a costly solvent removal step and less drug is needed. Drugs dissolve directly in the pre-cured adhesive which is then cured with water vapour. The manufacturing process is straightforward and environmentally friendly.

Download our Ibuprofen TEPI Patch Fact Sheet

Comparison of adhesion

Comparison of the adhesion of a TEPI patch with commerically available patches using a standard in vitro method

 

Results of a permeation enhancement study with different formulations of an Ibuprofen TEPI Patch (10wt% ibuprofen) using a skin-mimic (Strat-M) membrane

Results of a permeation enhancement study with different formulations of an Ibuprofen TEPI Patch (10wt% ibuprofen) using a skin-mimic (Strat-M) membrane